Attempts to Decrease Mother-to-Infant Transfer of HIV in Underdeveloped Countries
8 years ago
by ADMIN
in HIV and Pregnancy
HIV prevention ranks high on the priority list, especially among African nations that are seeing the highest rates of transmission. Challenges to implementing ways of preventing the transfer of HIV continue to crop up. One such challenge is in regards to HIV-positive women transferring the virus to their babies. Fortunately, for many communities, access to antiretroviral therapy means a measure of control over the spreading and transferring of HIV. It is in areas that are poor, isolated, and have limited medical resources where women are more likely to pass on the infection to their children.
Nigeria has continued to remain at the top of the list when it comes to death rates from HIV and also in the number of new infections each year. The nation is second only to South Africa for the number of HIV-positive children. To make matters worse, only 20% of those with HIV have access to antiretroviral treatments. Poverty certainly plays a part, and those in rural communities are even more limited in their access to certain types of medical care. One institute decided to implement an idea to help combat this growing problem.
Promoting Education, Screening, and Treatment to Prevent the Transfer of HIV
The idea was to efficiently provide medical testing, treatment, and education to those in rural communities. Women were given a package of services, and their husbands were also encouraged to get involved. Those in the villages who are responsible for providing healthcare were also instructed in how to provide a range of services. These included midwives, as their services are regularly sought after by those in the community. Cultural norms in certain areas include seeking medical attention and advice from individuals other than physicians.
The results of such efforts are promising. There was a decrease of nearly 75% in new infections for areas where this simple and cost-effective plan was put into practice. Results like this give hope that halting the spread of HIV can be achieved, even in regions where resources are limited. Such programs like this may be able to save many lives and have an influence on the transfer of HIV in developing lands.
New Study Clarifies the Link Between HIV and Tuberculosis
8 years ago
by ADMIN
in HIV Research
The link between HIV infection and the progression of other conditions is still a bit of a mystery. This is certainly the case when it comes to the body’s inability to keep in check the bacteria that causes tuberculosis, while in the presence of HIV. However, new insight into how the connection between the two conditions work, and how the immune system comes into play, has recently been published. This information could lead to further understanding of how to best treat the two conditions and support important immune system functions.
A large percentage of the population has the bacterium that develops into tuberculosis in their system. The immune system is generally quite adept at keeping the pathogen under control. For those who have this bacterium and are also infected with HIV, the tendency is to eventually develop tuberculosis as the HIV progresses. It was generally assumed that a weakened immune system, brought about by HIV infection, was the reason behind tuberculosis development in infected patients. This is not necessarily the case.
How HIV Progression Affects Tuberculosis in the Body
The published information painstakingly compared what was happening during each stage of HIV infection—with the effect on the immune system. What researchers found was that in the early stages of HIV infection, a function of the immune system diminishes. That component, called IL-10, is used to reduce inflammation. As HIV progresses, interferon response is noted. This is an antiviral immune response, but it dampens defense against tuberculosis.
The imbalance of immune support when the two infections are both present seems to be what accounts for the progression into tuberculosis. It should also be noted that other dangerous conditions can present suddenly in such an environment. Regulating the imbalance is what researchers are hoping to achieve as they continue to examine their findings. If successful, they will be able to modify the responses of the immune system to effectively combat both pathogens. This is important research as it relates to helping HIV-positive individuals to deal with secondary diseases as HIV progresses.
HIV Treatment Funding Is Out of Reach for Countries in Need
The battle against HIV has come a long way. Those living with the infection benefit from therapies now available. One of these benefits is a longer life expectancy. Worldwide, these implemented treatments not only improve quality and quantity of life, but it also limits the spread of the disease. Unfortunately, longer life equals more expense in lifetime treatment costs, which underdeveloped nations cannot support.
In spite of the good things being accomplished, the cost of maintaining what had been put into effect is already high and is increasing. Some of the countries hardest hit by HIV will experience the biggest cuts in funding. For these areas, future long-term care could be compromised. In Sub-Saharan Africa, home to some of the countries with the highest cases of HIV infections, studies were done to determine the cost of long-term therapy. The numbers are staggering. In order to maintain current treatment, account for new cases, and continue with prevention plans through the year 2050, it is estimated to cost over $260 billion. It’s a figure African countries simply can’t sustain.
Some Countries with the Greatest Need Have the Least Resources
The areas that were investigated are the ones that account for well over two-thirds of HIV infections in all of Africa. These nations do not have the resources to continue to provide necessary and ongoing care for HIV patients. Experts feel it’s vital to collect the needed funding now to ensure it is there for the future. Otherwise, lack of funds for treatment could lead to an increased prevalence of AIDS, as well as an increase in the spread of HIV.
As previously mentioned, long-term care is important for each individual who is HIV-positive. Part of the treatments include inhibiting the transfer of the virus. Stopping the spread of the disease is vital. Researchers emphasized the need for continued support in the fight against HIV, not only for the financial reasons but the moral ones as well. With so many people able to have a relatively healthy and normal life because of current plans in place, their lives are dependent on continued care and the funding that backs it.
New Look into HIV Cellular Infiltration
8 years ago
by ADMIN
in HIV Research
HIV is adept at making its way through cellular defenses in order to overtake the cell. Just how this happens has been the center of study for a long while. A better understanding of the processes involved can open doorways to keeping infections from spreading, or even occurring in the first place.
Cellular Infiltration and Cyclophilin A
The protein named cyclophilin A carries out numerous duties. It plays a key role in immune response, particularly when it comes to inflammation. Folding and sending off new proteins is also on its list of tasks. This protein is found in multiple tissues throughout the body. While much good is accomplished by cyclophilin A, too much of a good thing can be bad. In this case, conditions ranging from asthma to cancer can be responsible for the malfunction or overproduction of the protein. How does this relate to HIV and cellular infiltration?
HIV has an outer shell made up of proteins called a capsid. It is not known how, but the virus can dupe the cyclophilin A into creating a cover. This cloak binds to the HIV, which is then escorted into the nucleus of its cellular host. Once inside the center of the cell, the virus commandeers it. HIV then begins to copy its own genetic code, using the cellular mechanisms it overtook.
The picture painted by this information seems bleak, but there is a catch to the system. Like anything, balance is the key to success. The delicate systems cooperating together are likewise balanced in their own way. For example, researchers have found that too much of the protein can cause issues when binding to the virus. This can lead to a failed mission for the HIV. On the other hand, too little cyclophilin A, and the virus can be detected and destroyed by the immune system.
Now, scientists have the task of determining how best to use this new information in the fight against HIV infection. Having a better understanding of the inner workings can prove vital to developing new strategies against the virus, and the continued research is very promising.
HIV Therapies According to Gender
8 years ago
by ADMIN
in HIV Therapy
The approach to treating HIV is similar for all—male and female, young and old. Adjustments can be made according to certain factors. A particular dosage may work for one, but may not be optimal for another. One recently published study shows why this can happen, and how medical professionals can increase the effectiveness of HIV therapies for their patients.
HIV Therapies and Gender
Preventing infection is an important part of curbing the spread of HIV. The drug used to prevent viral transfer is called Truvada. Until recently, it had been noted that the drug was most effective in men. Researchers found that it seemed less effective in women. Further investigation revealed that differences in tissues contributed to how well Truvada worked at preventing infection.
HIV needs access to genetic material in order to infect its host. The more DNA that is present, the stronger the viral hold. For women, vaginal and cervical tissues have more DNA present than in other types of tissue. Rectal tissue is also in this category. This requires considerable more medication to curtail HIV activity.
Armed with this knowledge, scientists mathematically calculated specific drugs-to-DNA ratios. Using this formula, and testing the outcomes, has proven successful. When increased doses were given to women, the rate of HIV infections decreased and more closely matched the male outcomes based on doses previously tried.
What does this mean for HIV therapies now? In short, women do best when taking Truvada every day. This contrasts considerably to the couple times a week generally prescribed. For the male population, the current dosage works well. Due to the anatomical differences, women require more of the medication. When taken daily, the rate of infection effectively decreases for this group. Of course, no one should change his or her therapy before consulting a healthcare provider.
So far, Truvada is the only FDA-approved pharmaceutical used to prevent the spread of HIV infections. Now with more information on how best to harness its potential, the medical world is in a good position to help keep others from contracting and spreading the virus.
